Here's some of what is coming soon to NeurologyLive® this week.
Feature|Articles|June 30, 2025
Most Impactful Neurology Trial Readouts From Early 2025
Author(s)Marco Meglio, Isabella Ciccone, MPH
Overviewing the major clinical trial readouts in neurology from the first half of 2025, with data that could reshape patient care.
Advertisement
Advertisement
In the first half of 2025, the neurology field has seen a wave of major clinical trial readouts that may shape the future of care across multiple disease areas. From pivotal phase 3 results in Alzheimer disease (AD) and migraines to promising data in rare neuromuscular and autoimmune disorders, the latest findings could redefine treatment possibilities and advancing precision medicine in neurology. These readouts have garnered widespread attention from clinicians and researchers alike, offering critical insights into therapeutic efficacy, safety, and trial design innovation.
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
The phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement